ConClusions: Ex-vivo normothermic limb perfusion preserves limb physiology and function for at least 12 hours. Thermography and ICG angiography are valuable tools in the assessment of limb perfusion quality with the advantage of providing an immediate evaluation which allows for the visual identification of perfusion gradients and regions of mal-perfusion. Muscle contraction upon nerve stimulation, a uniform physiologic temperature and tissue oxygenation, and the distal dye distribution on angiography identify a successful perfusion. These methods may have important future implications on the decision to transplant or replant a perfused limb. Myoglobin and CK concentration increased in all limbs during ex vivo perfusion, but the functional significance of this is still to be determined.
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Yutaka Fukunaga, MD; Yuki IzawaIshizawa, MD, PhD; Yoshitaka Kihira, PhD; Yasumasa Ikeda, MD, PhD; Keisuke Ishizawa, PhD; Koichiro Tsuchiya, PhD; Toshiaki Tamaki, MD, PhD; Ichiro Hashimoto, MD, PhD inTRoDuCTion: Ischemic flap necrosis is often occurred by insufficient blood supply, which prolongs the treatment period and occasionally requires an additional surgery. Ischemic flaps generate an excess amount of free radicals which is regarded as a major factor of ischemic skin necrosis. Thus free-radical scavengers would be an effective drugs in improvement of flap survival. In our previous studies, we have reported nitrosonifedipine (NO-NIF), which is a photolytic compound of nifedipine, possesses a potent radical scavenging activity, and shows the favorable effects against vascular endothelial dysfunction and type 2 diabetic nephropathy. In this study, we evaluated the ameliorating effect of NO-NIF on the ischemic flap model mice.
MATERiAl AnD METHoDs: 9-10 weeks old Male C57BL/6 mice were divided into 2 groups, NO-NIF or control (n=6 in each group), respectively. A 1.0 × 3.0 cm cranially based random pattern flap was elevated on the dorsum of mice. NO-NIF 30 mg/kg or vehicle was injected subcutaneously immediate after the operation and once a day until evaluation. Seven days after surgery, the survival area was calculated as a percentage of the total flap area. To detect the oxidative stress, malondialdehyde (MDA) in the distal part of the flap at post-operative day 1 and 3 was measured by thiobarbituric acid reactive substances assay. Protein expression of p22phox, an essential component of NADPH-oxidase, in the flap was measured by western blotting.
REsulTs: At post-operative day 7, the flap survival area was significantly larger in the NO-NIF-treated mice than controls (78.29 ± 7.04% vs. 51.81 ± 6.85%, p=0.021). The amount of MDA significantly decreased in the NO-NIFtreated mice at post-operative day 3 (2.31 ± 0.28µmol/g protein vs. 4.21 ± 0.32µmol/g protein, p=0.001), whereas MDA was same level in the both groups at the post-operative day 1 (2.77 ± 0.61µmol/g protein vs. 2.96 ± 0.51µmol/g protein).
In a manner consistent with MDA levels, protein expression level of p22phox was decreased in the NO-NIF-treated mice at post-operative day 3 (p=0.002).
ConClusions:
We present the ameliorating effect of NO-NIF on ischemic flap survival. MDA and p22phox protein was decreased by NO-NIF treatment, which suggests the ameliorating effect was exerted via free radical scavenging. This investigation indicates that free-radical scavengers including NO-NIF are effective drugs in improvement of flap survival. The sufentanil sublingual tablet system is a non-invasive, patient-controlled analgesia (PCA) drug/ device product recently approved by the European Medicines Agency for treatment of acute moderate-to-severe post-operative pain in a hospital setting. A second sufentanil product, a 30 mcg tablet (ST) dispensed sublingually by a healthcare professional via a single-dose applicator, is
